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1. Introduction 
Ethidium bromide is one of the most studied DNA 
intercalating agents [ l-41 and behaves as a trypano- 
tidal agent [5]. Likewise it exhibits mutagenic prop- 
erties [6] and some antitumor activity against the 
L1210 leukemia of mice [7]. These biological effects 
could be related to the biological transformation of 
the amino groups into electrophilic species as nitrenium 
cation of nitroxyl radical known to bind covalently 
to DNA [8,9]. Such an activation process was described 
for several strong antitumor drugs like endoxan [IO] 
or ellipticine [ 11,121. After photoactivation ethidium 
azide shows the same biological effects as. those pro- 
duced by ethidium itself [ 131. This result seems to 
imply the covalent binding of ethidium to DNA which 
requires the previous biological activation of the drug. 
To test this assumption and to design more active 
derivatives, a study of the ethidium metabolism was 
performed [14]. Two metabolites were extracted 
from rat bile and purified by high-performance liquid 
chromatography (HPLC) [ 141. Here, the unambiguous 
determination of their chemical structure was achieved 
by mass and ‘H NMR spectroscopies. A possible path- 
way for biochemical transformation of ethidium is 
proposed. 
2. Experimental 
2.1. Chemical 
Ethidium bromide was purchased from Sigma 
Chemical Co. 
8-amino S-ethyl 6-phenylphenanthridinium chlo- 
ride I and 8-acetamido S-ethyl 6-phenylphenanthri- 
dinium acetate II were synthetized as in [IS] and 
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crystallized from ethanol. Their purity was checked 
by thin-layer chromatography on silica gel plates with 
a 4: 1: 1 mixture of butanol:acetic acid:water as eluent. 
2.2. Purification of ethidium metabolites 
Biliary samples from rats treated successively with 
Aroclor 1254 [ 161 and ethidium as in [ 141 were col- 
lected during 7 h, incubated at 37°C for 20 h with an 
equal volume of &lucuronidase (Escherichia coli type 
1, Sigma Chemical Co.) in 0.1 M acetate buffer (pH 5) 
(2000 units/ml). The samples were then extracted 
with n-butanol (l/l, v/v) and centrifuged at 6000 X g 
for 20 min. The butanolic phase was lyophilized and 
the residue dissolved in methanol. The metabolites 
were then separated by HPLC on a Waters reverse 
phase M-Bondapack-CN column (4.5 mm X 30 cm) 
using as eluent a degassed mixture of n-butanol:water: 
methanol, 90:8:2 (by vol.) containing ammonium 
acetate (5 X 1 Oe3 M); flow rate 1.2 ml/min. The reten- 
tion times are, respectively, 9,12 and 14 min for B’, 
A and ethidium bromide. HPLC was performed on a 
Waters Associates instrument equipped with a 6000 A 
pump, a U6K injector and a 440 UV detector. Detec- 
tion was made at h = 254 nm and recorded with a 
Houston Instrument 5210 omniscribe chart recorder. 
Before NMR and mass spectrometry experiments, the 
samples from HPLC were chromatographed on 
Sephadex LH20 using ethanol:sodium acetate 0.1 M, 
80:20 as eluent. The pure fractions were collected, 
then lyophilised. 
2.3. Mass spectrometry 
Mass spectra were obtained with a Varian MAT 
3 11 A spectrometer by field desorption using an anode 
heating current of 15-25 mA. 
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2.4. ‘H NMR spectroscopy 
‘H NMR spectra wer e recorded at 270 MHz in 
DMSO-de on a Bruker WH 270 MHz operating at 20°C 
in the Fourier transform mode. 
All chemical shifts are expressed in ppm with 
respect to the hexamethyldisiloxane (HMDS) signal 
used as an internal reference and are reliable to 
+ 0.01 ppm. 
3. Results and discussion 
Using HPLC techniques two ethidium metabolites, 
A and B were separated from the bile of rats treated 
with ethidium bromide after liver monooxygenase 
activation by Aroclor 1254 [ 141. The minor metabolite 
B is a glucuroconjugated derivative of ethidium as 
shown by its transformation into a new compound B’ 
under the action of fl-glucuronidase [ 141. 
3.1. Mass spectroscopy 
Fig.1 shows the mass spectra of ethidium bromide, 
metabolite A and deconjugated derivative B’ obtained 
by field desorption. In the mild conditions used, only 
the peaks corresponding to the quaternary ethidium 
ion and to the tertiary base after loss of the quaternary 
ethyl group are observed. However, based on the peak 
due to the ethidium ion at m/z = 3 14, the positions 
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of the highest mass peaks in the spectra of A and B’ 
correspond to the introduction of an acetyl group in 
A and both an acetyl-group and a hydroxyl-group in 
B’. The structure of A was confirmed by the similarity 
of its mass spectrum and HPLC retention volume with 
those of an authentic sample of 8-monoacetamido- 
ethidium obtained by an unambiguous synthesis [ 151. 
3.2. NMR spectroscopy 
Apart from some reports on ethidium [ 171 and its 
dimeric analogs [ 18,191 no systematic NMR studies 
were done on phenanthridinium derivatives. There- 
fore, the structural determination of ethidium metab- 
olites required a preliminary analysis of the NMR 
spectra of the g-amino 5-ethyl6phenylphenanthri- 
dinium chloride I and its 8-acetyl derivative II, which 
were obtained by an unambiguous synthesis. 
The NMR spectrum of I (fig.2b) shows an AMX 
part corresponding to the g-amino substituted ring, in 
which the more shielded proton (6.38 ppm) was at- 
tributed to H7 as for ethidium [ 171. On the basis of 
this assignment, the Hg and Hre protons were attributed 
from double resonance experiments whereas the 
remaining resonances were assigned starting from the 
H, signal, shifted downfield by the well-known peri 
effect. 
The introduction of an acetyl group on the g-amino 
substituent of I leads to the expected deshielding 
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Fig.1. Mass spectra of (a) ethidium bromide, (b) metabolite A and (c) deconjugated derivative B’ performed by field desorption 
technique. Anode heating current is respectively 15, 25 and 25 mA. 
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Fig.2.270 MHz ‘H NMR spectra of (a) ethidium bromide, (b) 8-amino S-ethyl 6-phenylphenanthridinium chloride I and (c) 
lacetamido S-ethyl 6-phenylphenanthridinium acetate II in DMSOd,; T = 20°C. 
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Table 1 
Chemical shifts of &amino S-ethyl 6-phenylphenanthridinium chloride I and chemical shifts 
differences between 8-amino 5ethyl6-phenylphen~anthridinium chloride I and 8-acetamido kthyl 
6-phenylphenanthridiium acetate II (ASII-I) or ethidium bromide (AI~E~-I), respectively 
Protons 1 2 3 4 I 9 10 
“I 8.91 7.93 7.86 8.46 6.38 7.58 8.82 
A%I-I +0.15 +0.11 +0.18 +0.14 +1.50 +0.80 +0.27 
AEEt-I -0.33 -0.64 - -1.14 -0.20 -0.10 -0.30 
These increments, expressed in ppm, were obtained from the NMR spectra of I, II and ethidium 
bromide performed in DMSOd,. Positive values correspond to a deshielding effect 
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Fig.3. 270 MHz ‘H NMR spectra of (a) metabolite A and (b) deconjugated derivative B’ in DMSOd,; T = 20°C. 
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Table 2 
Comparison between computed (b,h.) and observed (60bs) chemical shifts (in ppm) 
for the aromatic protons of metabolite A 
Protons 1 2 4 I 9 10 
6CalC 8.73 7.40 1.46 1.68 8.28 8.19 
6obs 8.73 1.33 1.37 7.70 8.10 8.17 
The8 cdc were computed using experimental chemical shifts of I and the increments 
A611-I and A6Bt-I of table 1. The observed chemical shifts 6,bs were measured from 
the NMR spectrum of A performed in DMSOd, at 20°C 
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effects (fig.2c) occurring mainly on the protons of 
the acetamido substituted ring as evidenced by the 
chemical shift differences A&,-, (table 1). The addi- 
tional peak at 1.96 ppm corresponds to the acetyl 
group (flg.2c). As compared to I, the NMR spectrum 
of ethidium (fig.2a) reflects the expected shielding 
effect due to the introduction of a 3-amino group as 
shown by the chemical shift differences ASET-1 
(table 1). 
The NMR spectrum of the metabolite A (fig.3a) 
exhibits two ABX systems in the aromatic region 
and a methyl signal at 1.96 ppm. The signals corres- 
ponding, respectively, to the acetamido and the amino 
rings and therefore the position of the acetyl group 
were fmally established from the very close agreement 
(table 2) between the experimental chemical shifts 
and those computed using the A&n-, and AGET- 
increments of table 1. Moreover, the methyl signal 
of the acetyl group appears at the same position 
(1.96 ppm) in the spectra of A and II. Therefore the 
methyl signal at 2.15 ppm in the spectrum of the 
3,8&cetylethidium (not shown) can be unambigu- 
ously assigned to the 3-acetyl group. 
The very low quantity of the deconjugated minor 
metabolite B’ obtained from preparative HPLC of rat 
bile extracts treated by &lucuronidase has required 
several lyophilisations in DzO in order to remove con- 
taminents from HPLC eluent (HzO, n-butanol, ammo- 
nium acetate, methanol). Therefore all exchangeable 
protons of this deconjugated metabolite do not appear 
in its spectrum. The ‘H NMR spectrum of B’ exhibits 
a singlet at 1.94 ppm (3H) partially overlapped by the 
contaminant counter-ion acetate resonance (1.88 ppm). 
This signal can easily be assigned to a 8-acetamido 
group by comparison with those of compounds II and 
A. The two coupled signals at 4.3 1 ppm (quadruplet 
2H) and 1.3 1 ppm (triplet 3H) confirm that this 
phenanthridinium derivative is still quaternized by an 
ethyl group. 
The aromatic part (fig.3b) shows two independent 
AMX and A’X’ systems. Double resonance experi- 
ments demonstrate that the signals at 7.44 ppm 
(doublet JAx = 2 Hz), 7.87 ppm (doublet of doublet 
J AM = 9 Hz, JAX = 2 Hz) and 8.33 ppm (doublet 
JAM = 9 Hz) are coupled and therefore located on the 
same ring. The two remaining resonances at 7.06 ppm 
Table 3 
Chemical shifts of the aromatic protons of 8-acetylethidium (= metabolite A) and of the 
deconjugated derivative B’ following two possible structural assumptions (g-or 2-hydroxy 
derivatives) 
Protons 1 2 4 7 9 10 
8-acetyl ethidium = A 8.13 7.33 7.37 7.10 8.10 8.17 
B’ = first assumption = 
8-acetyl9hydroxy ethidium 8.33 7.87 7.44 7.06 - 1.11 
B’ = second assumption = 
8acetyl 2-hydroxy ethidium 7.11 - 7.06 7.44 1.87 8.33 
These experimental values were measured from the NMR spectra of A and B’ performed in 
DMSO-d, 
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Table 4 
Coupling constants of ethidium bromide, its metabolites A and B’ and the phenanthridinium 
derivatives I and II 
Jl-2 51-3 J2-3 J2-4 J3-4 Jl-9 J9-10 
Ethidium bromide 9 - - 2a - 2.5 9 
B-amino 5ethyl6-phenyl 
phenanthridinium chloride I 8 2 8a 2a 8.5 2 9 
I-acetamido S-ethyl 6-phenyl 
phenanthridinium acetate II 8 2a 8a 2a 8.5 2 9 
8-acetyl ethidium 
= metabolite A 9 - - 2a - 2 9 
8-acetyl 2-hydroxy ethidium 
= metabolite B’ - - - - - 2 9 
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All J-values were directly measured on the spectra. When direct first order analysis of the spectra does 
not apply, a indicates that the given values are reliable to k 1 Hz only 
and 7.11 ppm exhibit neither ortho nor meta coupling 
since they are higher and sharper than the signals at 
7.44 ppm and 7.87 ppm. Therefore these protons 
should be in paru position one in respect to the other. 
The coupling constants of all the studied compounds 
are reported in table 4. 
Two structures could agree with the spectrum of 
B’ (tig.3b), either 8-acetyl9-hydroxy ethidium or 
8-acetyl2-hydroxy ethidium. 
In the first case, the OH-group being on the 9 posi- 
tion, the AMX system should be assigned to Hr, Hz 
and H4 and the A’X’ part to H7 and Hlc,. In that case, 
protons H2 and H4 would undergo a deshielding effect 
(see table 3) which cannot be explained by the intro- 
duction of the OH on the 9 position, since this group 
is a well-known upfield shift inducer. Therefore such 
a structure must be ruled out. 
In the second structure the OH-group was located 
on the 2 position and the AMX system can be assigned 
to protons H7, Hg and Hre whereas the A’X’ part cor- 
responds to Hr and H,+ In this case, as expected, all 
the aromatic resonances are upfield shifted (table 3). 
Therefore the 8-acetyl2-hydroxy ethidium structure 
could be attributed to this deconjugated metabolite 
B’. The larger than expected shielding effect on proton 
Hr (1.62 ppm) using the shielding induced in benzene 
by an ortho OH group (0.56 ppm) [20] could be 
explained by three factors: 
(i) B’ could be a phenolate ion and it is well-known 
that such ionization causes enhanced upfleld 
shifts [21]; 
(ii) Large discrepancies between calculated and ob- 
served chemical shifts were found when two sub- 
stituents are ortho to one another [21]; 
(iii) The substituent effects are more important in 
polycyclic systems than in benzene. Likewise the 
unexpected large shielding of Hre (0.44 ppm) 
could be related to a specific electronic distribu- 
tion in the tricyclic quaternary compound. 
4. Conclusion 
In this study, the structure of the main metabolite 
of ethidium extracted from rat bile wasunambiguously 
established as 8-acetyl ethidium (= 8-acetamido 3-amino 
S-ethyl 6-phenyl phenanthridinium). The identity 
between the compound isolated from this biological 
medium and an analytical sample synthetized as in 
[ 151 indicates that in both conditions the acetylation 
occurs on the more basic amino group in accordance 
with [22]. The minor metabolite is the glucurocon- 
jugated derivative of 8-acetyl2-hydroxy ethidium 
(= 8-acetamido 3-amino 5ethyl2-hydroxy 6-phenyl- 
phenanthridinium). 
Therefore, this study allows confirmation of the 
biological transformation process of ethidium bromide 
in liver cells proposed in [ 141. This metabolic pathway 
involves a cytosolic N-acetyltransferase leading to 
8-acetyl ethidium which could be hydroxylated 
through the action of microsomal monooxygenases 
(P-448 or PI-450 cytochromes), followed by glucuro- 
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Fig.4. Simplified scheme of the ethidium metabolism in rat 
liver. 
conjugation of the hydroxy derivative by UDP-glu- 
curonyl transferase [ 141 (fig.4). These results agree 
well with [23] on the biological transformation of 
phenanthridhrium drugs. 
Compound B’ could arise from the transposition 
of an iV-hydroxy ammo-3 ethidium derivative result- 
ing from the oxydation of the 3-amino group of com- 
pound A by liver enzymes. Formation of a highly 
mutagenic N-hydroxyamino derivative occurs in the 
case of 2aminofluorene [24]. Whatever the biological 
mechanism involved in the formation of compound 
B’, its qumone-imine structure could allow its cova- 
lent binding to DNA in vivo. Synthesis of large quan- 
tities of B’ is now in progress to check this hypothesis. 
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